U.S. shipments of COVID-19 molecular diagnostic tests reached 1 million per day for the week ending July 24, based on the latest data from AdvaMed’s national testing registry.
The medtech trade group launched the registry July 21 to aid state and federal pandemic responses.
“This incredible milestone is just the latest example of how the medical technology industry is rising to meet the challenges posed by the COVID-19 pandemic,” said AdvaMed president & CEO Scott Whitaker in a news release. “Widespread and widely available testing is key to our ability as a nation to overcome this public health crisis, and our industry is committed to providing the testing supplies and information health care providers need in order to achieve the necessary testing capacity.”
Daily molecular test runs increased by approximately 30% since June, reaching a peak of about 775,000 daily tests administered by mid-July, according to AdvaMed. FDA-authorized antibody testing is now available at scale with industry capacity to manufacture 100 million tests per month, the group noted.
The registry will provide weekly state- and national-level updates on the number of molecular, antigen, and antibody tests shipped in the U.S. AdvaMed and AdvaMedDx, the association’s division of diagnostics companies, developed the registry in partnership with 13 commercial diagnostics manufacturers: Abbott, BD, bioMérieux, Bio-Rad, Beckman Coulter, Cepheid, Hologic, Ortho Clinical Diagnostics, QIAGEN, Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers and Thermo Fisher Scientific.